Core Insights - The Chinese pharmaceutical industry is experiencing a surge in Business Development (BD) activities, with significant collaborations and licensing agreements being announced at the beginning of the year [1][3][8] - The total value of licensing agreements for Chinese innovative drugs reached approximately $135.65 billion (about 933.56 billion RMB) in the previous year, with 157 transactions recorded [3] - The trend of BD is expected to continue, driven by the increasing capabilities of domestic innovative drug development and the need for multinational corporations (MNCs) to fill pipeline gaps [5][8] BD Transaction Highlights - Frontier Biotech announced an exclusive licensing agreement with GlaxoSmithKline (GSK) for two small RNA products, with an upfront payment of $40 million (about 27.8 million RMB) and potential milestone payments totaling up to $950 million (about 6.594 billion RMB) [4] - Hengrui Medicine disclosed a partnership with Solstice Oncology, granting exclusive rights for the development and commercialization of HBM4003 outside Greater China, with an upfront payment exceeding $10.5 million (about 7.29 million RMB) and potential milestone payments of up to $1.1 billion (about 7.336 billion RMB) [3][4] Market Trends - The small RNA drug sector is gaining attention, with Frontier Biotech focusing on chronic disease treatments and showcasing potential for first-in-class or best-in-class candidates [6] - The rapid development of small RNA technologies is driving deeper industry collaborations, positioning small RNA drugs as a significant area for BD activities [7] - Domestic BD collaborations are increasingly focused on resource sharing and risk mitigation, contrasting with previous trends that emphasized international partnerships [8][9] Domestic Collaboration Growth - There has been a notable increase in domestic BD transactions, with companies like Zhongsheng Pharmaceutical and Jichuan Pharmaceutical engaging in licensing agreements to enhance their market presence [8][9] - The emphasis on domestic collaborations reflects a trend towards resource integration and technology sharing, aiming to accelerate product development and market entry [9]

Core Insights - The pharmaceutical industry in China is experiencing a surge in business development (BD) activities, particularly in the innovative drug sector, with significant transactions occurring in early 2026 [1][4][10] - Companies like Frontier Biotech and Hengrui Medicine have recently announced exclusive licensing agreements with multinational corporations, indicating a trend of collaboration aimed at global market access [1][4][5] BD Transaction Heat - In 2025, the total value of innovative drug licensing transactions in China reached $135.655 billion, with 157 deals reported [4] - In the first quarter of 2026, the total value of licensing transactions has already reached $33.28 billion, surpassing the highest quarterly figure from 2025 [4] - Hengrui Medicine's agreement with Solstice Oncology includes upfront payments exceeding $105 million and potential milestone payments of up to $1.1 billion [4] - Frontier Biotech's deal with GSK involves an upfront payment of $40 million and potential milestone payments totaling up to $950 million [5] Focus on Small Nucleic Acids - Frontier Biotech's recent licensing agreement highlights the growing interest in small nucleic acid drugs, which are seen as a promising third category of therapeutics alongside small molecules and antibody drugs [7][8] - The company is focusing on chronic disease treatments, with pipelines covering various conditions, indicating a strategic emphasis on innovative drug development [7] - The small nucleic acid sector has seen multiple transactions recently, reflecting its status as a key area for BD activities [7] Domestic Transactions on the Rise - There has been a notable increase in BD collaborations among domestic pharmaceutical companies, moving beyond simple "going global" narratives [9][10] - Recent domestic deals include collaborations between companies like Zhongsheng Pharmaceutical and Qilu Pharmaceutical, as well as partnerships involving Jichuan Pharmaceutical and Kangfang [9] - The focus of domestic BD is on resource sharing and risk mitigation, allowing companies with R&D strengths to partner with those possessing commercialization capabilities [10]

Core Viewpoint - The company has received FDA approval to conduct Phase II clinical trials for RAY1225, aimed at overweight or obese patients, and is actively seeking international collaboration for multi-center clinical research [1] Group 1 - The company confirmed that RAY1225 injection has been approved by the FDA for Phase II clinical research in the United States [1] - The company is pursuing international cooperation to organize and conduct multi-center clinical studies [1] - The goal is to complete the relevant research as soon as possible and apply for drug approval to provide more treatment options for patients [1]

Group 1 - The core viewpoint of the article is that Zhongsheng Pharmaceutical has signed a licensing agreement for the RAY1225 injection project with Qilu Pharmaceutical, which is expected to positively impact the company's cash flow and future operations [1] - The company has received the initial payment from Qilu Pharmaceutical, which will effectively supplement its cash flow [1] - This agreement is anticipated to optimize the company's cash flow structure and contribute to its future business development [1]

Group 1 - The company has signed a licensing agreement for the RAY1225 injection project with Qilu Pharmaceutical, which includes a $20 million upfront payment [2] - The company has confirmed receipt of the upfront payment, which will effectively supplement its cash flow and optimize its cash flow structure [2] - This licensing agreement is expected to have a positive impact on the company's future operational development [2]

Investment Rating - The report gives a "Buy" rating for the company, with a target price of 23.37 CNY based on a PE valuation of 57 times for 2026 [3][6]. Core Insights - The company is expected to benefit from a dual-driven strategy of traditional Chinese medicine (TCM) and chemical drugs, with a gradual clearance of the impact from centralized procurement on TCM business. The innovative drug pipeline is entering a harvest phase, with projected net profits for 2025-2027 being 290 million, 350 million, and 410 million CNY respectively, corresponding to EPS of 0.34, 0.41, and 0.48 CNY [3][9]. Summary by Sections 1. Dual-Driven Strategy of TCM and Chemical Drugs - The company has a rich product layout and maintains stable performance, with a focus on TCM and high-end generic drugs. The revenue from TCM has historically contributed over 50% of total revenue, while the share of chemical drugs has increased from 24% in 2016 to 36% in 2024 [13][16]. - The company launched an employee stock ownership plan in 2024 to incentivize core personnel, focusing on performance assessment and innovative drug development [23][24]. 2. Innovative Product Data and Growth Potential - The company has several innovative products entering commercialization or late-stage clinical trials. Notably, RAY1225, a dual-target drug for obesity and diabetes, has shown superior efficacy in clinical trials compared to existing treatments [27][29]. - ZSP1601, a first-in-class drug for NASH, is currently in IIb phase clinical trials and has demonstrated promising results in reducing liver inflammation markers [45][49]. 3. Core TCM Products and Market Recovery - The company's core TCM product, Compound Thrombus Tong Capsule, has maintained a leading market share in the ophthalmic TCM sector. As the impact of centralized procurement diminishes, sales are expected to stabilize and recover [9][18]. - The Brain Thrombus Capsule, another key product, has shown stable clinical demand and is projected to continue its steady growth [9][18].

Investment Rating - The report gives a "Buy" rating for the company, with a target price of 23.37 CNY based on a PE valuation of 57 times for 2026 [3][6]. Core Insights - The company is expected to benefit from a dual-driven strategy of traditional Chinese medicine (TCM) and chemical drugs, with a gradual clearance of the impact from centralized procurement on TCM business. The innovative drug pipeline is entering a harvest phase, with projected net profits for 2025-2027 being 290 million, 350 million, and 410 million CNY respectively, corresponding to EPS of 0.34, 0.41, and 0.48 CNY [3][9]. Summary by Sections 1. Dual-Driven Strategy of TCM and Chemical Drugs - The company has a rich product layout and maintains stable performance, with a focus on eye care, cardiovascular, respiratory, and digestive diseases. Revenue for the first three quarters of 2025 was 1.89 billion CNY, a decrease of 1.0% year-on-year, while net profit attributable to the parent company was 250 million CNY, an increase of 68.4% [13][9]. - The core TCM product, Compound Thrombus-Relieving Capsule, is a unique original formulation with a leading market share in the domestic ophthalmic TCM sector. The impact of centralized procurement is gradually being digested, and sales are expected to stabilize [9][10]. 2. Innovative Product Data and Growth Potential - The company has multiple innovative products entering commercialization or late-stage clinical trials. The PB2-targeted RNA polymerase inhibitor, Anladiwei Tablets, was approved in May 2025 for treating adult uncomplicated influenza, showing competitive advantages over Oseltamivir [9][27]. - The GLP-1/GIP dual-target drug RAY1225 for obesity and diabetes has entered Phase III clinical trials, with promising results indicating better weight loss efficacy compared to existing treatments [27][29]. 3. Financial Forecast and Investment Recommendations - The company’s revenue is projected to recover, with expected revenues of 2.803 billion, 3.126 billion, and 3.447 billion CNY for 2025, 2026, and 2027 respectively, reflecting growth rates of 13.6%, 11.5%, and 10.3% [5]. - The report emphasizes the importance of innovation and performance assessment, with an employee stock ownership plan launched in 2024 to incentivize core personnel [23][24].

Core Viewpoint - Zhongsheng Pharmaceutical announced a licensing agreement with Qilu Pharmaceutical for the production and commercialization of RAY1225 injection in China, retaining global intellectual property rights and MAH status [1] Group 1 - Zhongsheng Ruichuang signed a licensing agreement with Qilu Pharmaceutical on January 16, 2026 [1] - The agreement includes an upfront payment of 200 million RMB and potential milestone payments up to 800 million RMB for development and sales [1] - Zhongsheng Ruichuang will also receive a double-digit percentage of net sales as royalties [1]

Financial Performance - The company's net profit for 2025 is expected to be between RMB 260 million and RMB 310 million, representing a year-on-year growth of 186.91% to 203.62% [1] - The net profit after deducting non-recurring gains and losses is projected to be between RMB 270 million and RMB 320 million, with a growth rate of 203.72% to 222.93% [1] Strategic Partnerships - A licensing agreement was signed with Qilu Pharmaceutical on January 16, 2026, for the production and commercialization of RAY1225 injection in China, with an upfront payment of RMB 200 million [3] - The total potential milestone payments from Qilu Pharmaceutical could reach RMB 800 million, in addition to a double-digit royalty on net sales [3] Innovation and R&D Pipeline - The company focuses on innovative drug development for metabolic diseases and respiratory diseases, with two innovative drugs already approved for market [6][7] - RAY1225 injection, a dual receptor agonist, is currently undergoing multiple Phase III clinical trials for obesity and type 2 diabetes, showing promising efficacy and safety [11][12] - The company is also developing ZSP1601 tablets for metabolic dysfunction-related fatty liver disease, which has shown significant results in clinical trials [6] Market Opportunities - The market for metabolic-associated fatty liver disease (MASH) is substantial, with no approved treatments currently available, indicating a significant unmet clinical need [14] - Obstructive sleep apnea (OSA) affects approximately 176 million people in China, with RAY1225 injection potentially offering a new treatment option for this condition [16][18] Clinical Trial Progress - RAY1225 injection has completed Phase II trials with positive results, and Phase III trials are ongoing for various indications, including obesity and type 2 diabetes [12][17] - The company is committed to advancing its clinical trials with high quality and speed, focusing on innovative solutions for metabolic diseases and respiratory conditions [13]

Core Viewpoint - The company, Zhongsheng Pharmaceutical, has received FDA approval to conduct Phase II clinical trials for its RAY1225 injection in overweight or obese patients in the United States, indicating a significant step in its international market expansion strategy [1] Group 1 - The company emphasizes the importance of overseas market opportunities for its products [1] - The company is accelerating its internationalization efforts [1]